Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

PAX-1 is under clinical development by Komipharm International and currently in Phase I for Kidney Cancer (Renal Cell Cancer).

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Kidney Cancer (Renal Cell Cancer).

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Insurance firms in South Korea shift focus to guaranteed products for stable profits Insurers in South Korea prioritize ...

Researchers are making strides in improving gene therapies for genetic diseases, particularly chronic kidney disease, using adeno-associated virus, or AAV, vectors. While AAV-based treatments have ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...

A University of Nottingham study revealed that prolonged paracetamol use in individuals 65 and older increases the risk of gastrointestinal, cardiovascular, and renal complications. Researchers ...

With seven agents approved for renal cell carcinoma within the past few years ... The presence of poor Karnofsky scores and liver or CNS disease may affect the outcome of these patients much ...